18219 Investors following Aurobindo Pharm. Share this News with them.
0
Like this story, share it with millions of investors on M3
European acquisitions to boost Aurobindo's revenues
Aurobindo Pharma Ltd, the Rs 1,472-crore pharma major, is upbeat on the European markets, following its two key acquisitions in 2006. With the UK-based Milpharm Ltd and the Netherlands-based Pharmacin International in its fold, the company expects to substantially boost its revenues in the fiscal 2007-08.
Aurobindo Pharma Ltd , the Rs 1,472-crore pharma major, is upbeat on the European markets, following its two key acquisitions in 2006. With the UK-based Milpharm Ltd and the Netherlands-based Pharmacin International in its fold, the company expects to substantially boost its revenues in the fiscal 2007-08.
The Hyderabad-based Aurobindo Pharma, with strengths in generic pharmaceuticals and active pharmaceutical ingredients (APIs), hopes to gain on two counts through these acquisitions. First, it would quickly achieve a large portfolio of products with regulatory approvals in Europe. Secondly, it would gain new markets and reach them faster.
|
Budget: 2008, 2009, 2010, 2011, 2012 |
Intuit Money Manager |
RBI Credit Policy | Union Budget | Budget 2012
| Economic Survey
| Railway Budget
| Financial Glossary
|
Message Board |
Moneybhai |
Connect.in.com |
Business Yellow Pages |
India's Premiere Technology Guide | History India
| Up Polls | Latest News
| Uninor | LIC Housing Finance | Tata Steel | Reliance Industries | BSE Sensex | Aurobindo Pharma | Namma Metro | Reliance Communications | Mahindra Satyam | Vodafone Essar 
The Hyderabad-based Aurobindo Pharma, with strengths in generic pharmaceuticals and active pharmaceutical ingredients (APIs), hopes to gain on two counts through these acquisitions. First, it would quickly achieve a large portfolio of products with regulatory approvals in Europe. Secondly, it would gain new markets and reach them faster. 
